[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100479405":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":18,"collaborators":7,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":7,"acronym":7,"eligibilityCriteria":25,"healthyVolunteers":22,"sex":26,"minAge":27,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":28,"phases":7,"briefSummary":29,"conditions":30,"keywords":32,"overallStatus":42,"whyStopped":7,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":47,"locationsCount":7},{"fullName":5,"class":6},"Pfizer","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Ritlecitinib","capsules",[14],{"name":15,"role":16,"phone":7,"phoneExt":7,"email":17},"Pfizer Cares","CONTACT","PfizerCares@Pfizer.com",{"type":19,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100479405","pre-approval-single-patient-expanded-access-for-ritlecitinib-pf-06651600-100479405",false,"NCT05522556","Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)","Must have ≥ 50% hair loss on scalp due to Alopecia Areata (AA) and be intolerant or have inadequate response to all commonly used AA therapies accessible in the country. Additional eligibility criteria may be required.","ALL","12 Years","EXPANDED_ACCESS","Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.",[31],"Alopecia Areata",[33,34,35,36,37,38,39,40,41],"Alopecia Areata (AA)","Alopecia","Patchy AA","Alopecia Universalis (AU)","Alopecia Totalis (AT)","Ophiasis","Eyelash Loss","Eyebrow Loss","Hair Loss","AVAILABLE","2025-11-17",{"date":45,"type":46},"2025-11-18","ACTUAL",{"name":5,"class":6}]